NASDAQ:IDYA IDEAYA Biosciences Q2 2026 Earnings Report $36.22 +0.82 (+2.32%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast IDEAYA Biosciences EPS ResultsActual EPS-$1.22Consensus EPS -$1.06Beat/MissMissed by -$0.16One Year Ago EPS-$0.88IDEAYA Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$8.02 millionBeat/MissN/AYoY Revenue Growth+8,800.00%IDEAYA Biosciences Announcement DetailsQuarterQ2 2026Date8/4/2026TimeBefore Market OpensConference Call DateTuesday, August 4, 2026Conference Call Time6:00AM ETUpcoming EarningsIDEAYA Biosciences' Q3 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) IDEAYA Biosciences Earnings HeadlinesIDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 4 at 6:00 AM | prnewswire.comIDEAYA Biosciences (IDYA) Expected to Post Quarterly Earnings on MondayAugust 3 at 5:31 AM | americanbankingnews.comSMX: A Tiny Ticker with a Massive Global Growth Story!SMX (Security Matters) is building technology designed to solve one of sustainability's biggest problems: proving that recycled materials are real, traceable, and valuable. By embedding invisible molecular markers into plastics and other materials, SMX creates a digital identity that tracks origin and lifecycle data from collection through reuse. As governments and manufacturers push for stronger sustainability standards, SMX is positioning its verification technology at the center of the shift toward traceable, trusted recycled materials.August 4 at 1:00 AM | Smallcaps Daily (Ad)Ideaya Biosciences Inc (IDYA)July 31, 2026 | fr.investing.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 31, 2026 | prnewswire.comIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted ...July 27, 2026 | finance.yahoo.comSee More IDEAYA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email. Email Address About IDEAYA BiosciencesIDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications. Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization. Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.View IDEAYA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Chip Stock Making a Quiet Move Toward DominanceApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-CapsMarriott’s Earnings Drop May Be Missing the Bigger Fee Growth StoryDodging Deutsche Telekom: T-Mobile's Strategic WinSpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
